Top Markets
#1 WYDE: End Hunger WYDE: End Hunger +2.71%
#2 MetaDAO MetaDAO +2.37%
#3 StonkBroker StonkBroker +2.30%
#4 Not in Employment, Education, or Training Not in Employment, Education, or Training +2.27%
#5 PulseX PulseX +1.94%
#6 The Grays Currency The Grays Currency +1.93%
#7 Dual Dual +1.86%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +1.67%
#9 Fractal Bitcoin Fractal Bitcoin +1.59%
#10 Wrapped Pulse Wrapped Pulse +1.56%
Coin of the day
WYDE: End Hunger WYDE: End Hunger
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Adagene Inc. Adagene Inc.

Adagene Inc.

ADAG
Classifica tra le azioni #19939
Adagene Inc. functions as a clinical-stage biopharmaceutical organization,... Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
Prezzo delle azioni
$3.88
Ultima sincronizzazione: 2026-08-25
Capitalizzazione di mercato
$146.08M
Variazione (1 giorno)
-0.51%
Variazione (1 anno)
63.71%
Paese
CN
Scambia Adagene Inc. (ADAG)

Categoria

Healthcare
Ricavi di Adagene Inc. (ADAG)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Adagene Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Adagene Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH